Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
Yan XieBenjamin BoweAndrew K GibsonJanet B McGillYan YanGeetha MaddukuriZiyad Al-AlyPublished in: Diabetes care (2020)
Among people with type 2 diabetes, empagliflozin use was associated with eGFR preservation, a greater decline in BMI, and a reduced risk of MAKE compared with other non-SGLT2i antihyperglycemics.